Abstract
Oxidative stress is implicated in the pathogenesis of neurodegenerative diseases, including sporadic Alzheimer´s disease (AD). Mitochondrial DNA (mtDNA) deletions are markers of oxidative damage and increase with age. To unravel the impact of mtDNA damage on AD development, we analyzed mtDNA deletion levels in diverse neuronal cell types of four brain regions (hippocampal CA1 and CA2 regions, nucleus tractus spinalis nervi trigemini, and the cerebellum) that exhibit differing levels of vulnerability to AD related changes at progressive Braak stages compared with age-matched controls. Neurons from these four brain regions were collected using laser microdissection, and analyzed using quantitative polymerase chain reaction (qPCR). Although, no correlation between mtDNA deletion levels and AD progression were found, the data revealed regional and cell type specific selective vulnerability towards mtDNA deletion levels. In conclusion, unexpected results were obtained as granule cells from the cerebellum and neurons from the nucleus tractus spinalis nervi trigemini of the brain stem displayed significant higher mtDNA deletion levels than pyramidal cells from hippocampal CA1 and CA2 region in age and AD.
Keywords: Alzheimer´s disease, deletion, neurodegeneration, neuronal mitochondrial DNA, oxidative stress, selective vulnerability.
Current Alzheimer Research
Title:Neuron-Specific Mitochondrial DNA Deletion Levels in Sporadic Alzheimer´s Disease
Volume: 10 Issue: 10
Author(s): Anne Gerschütz, Helmut Heinsen, Edna Grünblatt, Anne K. Wagner, Jasmin Bartl, Christoph Meissner, Andreas J. Fallgatter, Safa Al-Sarraj, Claire Troakes, Isidro Ferrer, Thomas Arzberger, Jürgen. Deckert, Peter Riederer, Matthias Fischer, Thomas Tatschner and Camelia M. Monoranu
Affiliation:
Keywords: Alzheimer´s disease, deletion, neurodegeneration, neuronal mitochondrial DNA, oxidative stress, selective vulnerability.
Abstract: Oxidative stress is implicated in the pathogenesis of neurodegenerative diseases, including sporadic Alzheimer´s disease (AD). Mitochondrial DNA (mtDNA) deletions are markers of oxidative damage and increase with age. To unravel the impact of mtDNA damage on AD development, we analyzed mtDNA deletion levels in diverse neuronal cell types of four brain regions (hippocampal CA1 and CA2 regions, nucleus tractus spinalis nervi trigemini, and the cerebellum) that exhibit differing levels of vulnerability to AD related changes at progressive Braak stages compared with age-matched controls. Neurons from these four brain regions were collected using laser microdissection, and analyzed using quantitative polymerase chain reaction (qPCR). Although, no correlation between mtDNA deletion levels and AD progression were found, the data revealed regional and cell type specific selective vulnerability towards mtDNA deletion levels. In conclusion, unexpected results were obtained as granule cells from the cerebellum and neurons from the nucleus tractus spinalis nervi trigemini of the brain stem displayed significant higher mtDNA deletion levels than pyramidal cells from hippocampal CA1 and CA2 region in age and AD.
Export Options
About this article
Cite this article as:
Gerschütz Anne, Heinsen Helmut, Grünblatt Edna, Wagner K. Anne, Bartl Jasmin, Meissner Christoph, Fallgatter J. Andreas, Al-Sarraj Safa, Troakes Claire, Ferrer Isidro, Arzberger Thomas, Deckert Jürgen., Riederer Peter, Fischer Matthias, Tatschner Thomas and Monoranu M. Camelia, Neuron-Specific Mitochondrial DNA Deletion Levels in Sporadic Alzheimer´s Disease, Current Alzheimer Research 2013; 10 (10) . https://dx.doi.org/10.2174/15672050113106660166
DOI https://dx.doi.org/10.2174/15672050113106660166 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (Thematic Issue: Disease Control and Active and Healthy Ageing: New Paradigms of Therapeutic Strategy)
Current Pharmaceutical Design Click Chemistry, A Potent Tool in Medicinal Sciences
Current Medicinal Chemistry Paediatric Antiretroviral Drug Targets
Infectious Disorders - Drug Targets CADD Modeling of Multi-Target Drugs Against Alzheimer's Disease
Current Drug Targets The Prevalence of Frailty in Patients Admitted to Hospital with Vertebral Fragility Fractures
Current Rheumatology Reviews Dietary Approaches and Supplements in the Prevention of Cognitive Decline and Alzheimer's Disease
Current Pharmaceutical Design Catatonia in Affective Disorders
Current Psychiatry Reviews Cognitive Stimulation: The Evidence Base for its Application in Neurodegenerative Disease
Current Alzheimer Research Preface: What is Aging for? That Remains the Question
Current Aging Science Antiviral Treatment of Cytomegalovirus Infection
Infectious Disorders - Drug Targets Coumarins: Auspicious Cholinesterase and Monoamine Oxidase Inhibitors
Current Topics in Medicinal Chemistry Low Levels of High Density Lipoprotein Increase the Severity of Cerebral White Matter Changes:Implications for Prevention and Treatment of Cerebrovascular Diseases
Current Alzheimer Research Role of Mammalian Target of Rapamycin in Atherosclerosis
Current Molecular Medicine Neuroprotective Therapies for Alzheimers Disease
Current Pharmaceutical Design Dynamics of Nicotinic Acetylcholine Receptors and Receptor-Associated Proteins at the Vertebrate Neuromuscular Junction
Current Alzheimer Research Berberine: A Plant-derived Alkaloid with Therapeutic Potential to Combat Alzheimer’s disease
Central Nervous System Agents in Medicinal Chemistry Clinical Pharmacology of Non-Steroidal Anti-Inflammatory Drugs: A Review
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The ‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) Trial: A Step Forward in the Treatment of Early Breast Cancer
Reviews on Recent Clinical Trials Patients with Increased Non-Ceruloplasmin Copper Appear a Distinct Sub-Group of Alzheimer's Disease: A Neuroimaging Study
Current Alzheimer Research The Glutamate Hypothesis in ALS: Pathophysiology and Drug Development
Current Medicinal Chemistry